COVID-19

Georgetown University COVID-19 Related Technologies

1. Detection of Bacterial and Viral Pathogens Using Fluorescence Activated Sensing Technology (FAST System)
2. RACK1 Inhibitors for Treatment of Viral Infections
3. Applying State-of-Being to Healthcare Delivery
4. SafeScope Mask
5. Mint Mask

For information on COVID-19 Licensing Guidelines please visit the following link: https://otc.georgetown.edu/covid19-contracts/

A Fast and Accurate COVID-19 Test: Georgetown University researchers have engineered a next generation pathogen detection system that has been shown to be extremely sensitive and specific and therefore to have extremely low false positive and false negative rates. It is as rapid or faster than other methods and can also be automated and used to test for multiple types of organisms simultaneously (“multiplexed”). We are kindly asking your support of this campaign that will allow researchers to use this groundbreaking technology to develop a high-fidelity rapid molecular test for detecting the COVID-19 virus. To support this campaign for a faster, more accurate COVID-19 test please visit the following link: https://www.givecampus.com. We appreciate your consideration of making a gift and sharing this important work with others who may also be interested in doing so.

COVID-19 Research Opportunities: Unique Ways to Help

• Please visit the following link for COVID-19 funding opportunities. These lists will be updated as new opportunities arise: COVID-19 Funding Opportunities

• Georgetown University Medical Center is supporting 15 teams of investigators conducting research that covers a remarkable breadth and depth of critically important problems related to COVID-19: GUMC COVID-19 Research Projects
• ASGCT is hosting a two-day, virtual scientific symposium September 15-16 that will highlight the advances in understanding SARS-Cov2 and treating COVID-19. If you or your colleagues are involved in what has become the most important scientific area of research, this is your opportunity to present your cutting-edge science. You can submit an abstract now on ASGCT’s abstract submission site by July 31. Abstract notifications will be sent in August. The abstract categories are: Diagnostics, Vaccine strategies, Gene therapies, Cell therapies. The event is complementary to attend and open to ASGCT members and non members. More information will be available in the coming weeks. Questions? Please contact Alex Peterson, Education Program Manager, at apeterson@asgct.org.

• Wellspring announced the public availability of a free community website devoted to pooling worldwide research and technology efforts in the fight against SARS-CoV-2, also known as the novel coronavirus or COVID-19. They brought together technologies, startups, and researcher profiles into one centralized location. More information can be found on the following link: COVID-19 Research Collaborative
• The national NIH-funded CTSA network consists of 60 centers of clinical and translational research excellence across the country (called CTSA “hubs”) that support large multi-site clinical trials, which can be implemented and completed quickly and efficiently and have the power to generate meaningful and actionable results. Resources include:
  1. GHUCCTS Pilot Projects (GHUCCTS)
  2. NOSIs of the National Center for Advancing Clinical and Translational Science (NCATS)
  3. CTSA Trial Innovation Network (TIN)
  4. COVID-19 Collaboration Platform (COVID-CP)
  More information on GHUCCTS CTSA COVID-19 Research Initiatives can be found on the following link: http://www.georgetownhowardctsa.org
• Scientists worldwide are racing to develop more than 160 new drug and vaccine candidates to combat the pandemic, GEN reports in a comprehensive new A-List: Drug and Vaccine Candidates in Development

• NIH to launch public-private partnership to speed COVID-19 vaccine and treatment options: https://www.nih.gov/news-events
• In response to the COVID-19 pandemic, the White House and a coalition of leading research groups have prepared the COVID-19 Open Research Dataset (CORD-19) of over 44,000 scholarly articles, including over 29,000 with full text, about COVID-19, SARS-CoV-2, and related corona viruses,  freely available to the global research community to apply recent advances in natural language processing and other AI techniques to generate new insights in support of the ongoing fight against this infectious disease: COVID19 Open Research Dataset Challenge (CORD-19)
• Research and development collaborations regarding corona virus. BIO is providing this forum for products and services, to facilitate the exchange of information and the opportunity to expedite useful connections between and among the users of this website: Bio’s Forum (hub.bio.org)
• The Pandemic Response Hackathon is a virtual hackathon aimed at better understanding and mitigating the spread of COVID-19 and future pandemics: The Pandemic Response Hackathon (datavant.com)
• Summary of COVID19 Situation & Supply Needs: Open Source COVID19 Medical Supplies
• Relecura is an AI-based technology company based in the SF Bay Area offering an IP and technology analysis platform and automated patent classification tools, freely available to Corona virus researchers until May 31st. Researchers may email to researchers@relecura.com indicating their name, title, and the name of the organization. On a related note, their technical exploration tool, Tech Explorer, is available to all researchers for free: Tech Explorer Tool
• The Biotechnology Innovation Organization (BIO) hosted a productive virtual summit intended to foster collaboration among key government agencies and biopharmaceutical innovators with one goal: eradicating Covid-19: BIO Coronavirus Collaboration Initiative Summit Day 1
• BARDA Opportunities for Coronavirus Researchers; Funding Awards up to $750,000 available: BARDA EZ BAA Program
• The U.S. government is providing a portal for the 2019 novel coronavirus (COVID-19) medical countermeasures task force as a single point of entry for the submission of market research packages and meeting requests from interested stakeholders: BARDA TechWatch Meeting
• UAEM (Universities Allied for Essential Medicines) Presentation on Engaging University Leaders in the access to medicines movement is available here. For more information on UAEM’s work please visit their website: https://www.uaem.org/